Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)

Anemia is a common complication of chronic kidney disease (CKD), with erythropoietin deficiency being the major contributing factor. The availability of erythropoiesis-stimulating agents (ESAs) has been a seminal advance in the treatment of anemia related to chronic kidney disease. Over the course o...

Descripción completa

Detalles Bibliográficos
Autores principales: Panchapakesan, Usha, Sumual, Siska, Pollock, Carol
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673829/
https://www.ncbi.nlm.nih.gov/pubmed/17722510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673829/
https://www.ncbi.nlm.nih.gov/pubmed/17722510

Ejemplares similares